Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04919694
Other study ID # yanghs20210106
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date July 1, 2021
Est. completion date December 31, 2023

Study information

Verified date June 2021
Source Sun Yat-sen University
Contact Hua sheng Yang, M.D,PHD
Phone +8620-87331539
Email yanghs64@162.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether combination of orbital compression surgery with strabismus surgery is better than strabismus surgery after orbital compression surgery in the treatment of moderate-to-severe thyroid associated ophthalmopathy


Description:

This study will be a interventional case series. Patients with moderate-to-severe thyroid associated ophthalmopathy will be randomized to receive combination of orbital compression surgery with strabismus surgery or strabismus surgery after orbial compression surgery.Patients will be followed for 6 months.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 60
Est. completion date December 31, 2023
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - moderate-to-severe thyroid associate ophthalmopathy - CAS=3 score - monocular strabismus,deviation=20° or 35? - stable thyroid function for at least 6 months, confirmed by an endocrinologist Exclusion Criteria: - any previous disease in the study eye. - any previous systematic disease

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
combination of orbital compression surgery and strabismus surgery
combination of orbital compression surgery and strabismus surgery at the same time
orbital compression
orbital compression

Locations

Country Name City State
China Zhongshan Ophthalmic Center, Sun Yat-sen University Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary quality of life ,measured by GO-QoL(quality of life with Grave's Orbitopathy) . All GO-QoL questions were scored as 'severely limited' (one point), 'a little limited' (two points) or 'not limited at all' (three points). The questions 1-8 for visual functioning (VF) and questions 9-16 for appearance (AP)were summed to produce two raw scores from 8 to 24 points and then transformed to two total scores from 0 to 100 by the following formula: total score = [(raw score - 8)/16 9 100]. In both cases, higher total scores indicate better QoL. When there were missing values, total scores were calculated for the remaining completed items. The transformation was then adjusted to total score = [(raw score - *)/(2x*) x100] where * is the number of completed items. 6 weeks after surgery
Primary quality of life, measured by GO-QoL(quality of life with Grave's Orbitopathy) . All GO-QoL questions were scored as 'severely limited' (one point), 'a little limited' (two points) or 'not limited at all' (three points). The questions 1-8 for visual functioning (VF) and questions 9-16 for appearance (AP)were summed to produce two raw scores from 8 to 24 points and then transformed to two total scores from 0 to 100 by the following formula: total score = [(raw score - 8)/16 9 100]. In both cases, higher total scores indicate better QoL. When there were missing values, total scores were calculated for the remaining completed items. The transformation was then adjusted to total score = [(raw score - *)/(2x*) x100] where * is the number of completed items. 6 months
Secondary strabismus status angle of deviation including up-gaze, down-gaze ,left and right-gaze 6 weeks after surgery
Secondary strabismus status angle of deviation including up-gaze, down-gaze ,left and right-gaze 6 months after surgery
See also
  Status Clinical Trial Phase
Withdrawn NCT06087731 - Efficacy and Safety of Tocilizumab for TAO Phase 2
Recruiting NCT05110040 - Multi-model Image of Immunosuppressive Agents in TAO N/A
Recruiting NCT06112340 - A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) Phase 2/Phase 3
Recruiting NCT03107078 - Using A Novel Classification System in Intravenous GCs Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial Phase 4
Recruiting NCT04548284 - Study of Therapeutic Value of Periorbital Injection of Glucocorticoid in Mild TAO Phase 3
Recruiting NCT03515863 - Natural History and Risk Factors of TAO
Not yet recruiting NCT06392906 - Orbital Radiotherapy in Grave's Ophthalmopathy 1 Week vs 2 Weeks (OraGO-1 Trial) Phase 3
Recruiting NCT06226545 - A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease Phase 2
Completed NCT00150111 - Rituximab in the Treatment of Graves' Disease Phase 1/Phase 2
Completed NCT03110848 - Effects of Atorvastatin in Graves' Orbitopathy (GO) Phase 2
Recruiting NCT04662190 - Evaluation of the Efficacy and Safety of 3D Printing for Orbital Surgery. N/A
Active, not recruiting NCT05276063 - A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) Phase 2/Phase 3
Recruiting NCT03131726 - Treatment of Graves´Ophthalmopathy With Simvastatin (GO-S) Phase 3
Completed NCT02766660 - Optic Disc, Macula, and Retinal Nerve Fiber Layer Measurements Obtained by OCT in Thyroid Associated Ophthalmopathy N/A
Active, not recruiting NCT06269393 - A Study of IBI311 in Subjects With Steroid-resistant, Thyroid Associated Ophthalmopathy Phase 3
Not yet recruiting NCT03098225 - A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' Orbitopathy Phase 4
Recruiting NCT05112211 - Multi-model Image of Doxycycline in TAO N/A